Comparison of the cost-effectiveness of milnacipran (a SNRI) with TCAs and SSRIs: a modeling approachEUROPEAN PSYCHIATRYIF6.72020-04-169PREAI
DEVELOPMENT OF A PATIENT-REPORTED QUESTIONNAIRE IN PATIENTS WITH CHRONIC PRURITUSVALUE IN HEALTHIF62017-10-010OAAI
DEVELOPMENT OF A TOOL TO QUANTIFY AN INDIVIDUAL'S HISTORY OF SUN EXPOSURE: QUALITATIVE PHASE OF THE DEVELOPMENT OF THE SUN EXPOSURE QUESTIONNAIREVALUE IN HEALTHIF62017-10-010OAAI
A TIME AND MOTION COST ANALYSIS OF ORAL VINORELBINE VERSUS IV CHEMOTHERAPIES FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) AND METASTATIC BREAST CANCER (MBC)FROM CHINESE SOCIETAL PERSPECTIVEVALUE IN HEALTHIF62016-11-010OAAI
IMPACT OF GLUCOSAMIN AND CHONDROITIN SULFATES COMBINATION (GCSC) ON THE BURDEN OF OSTEORTHRITIS OVER 6 MONTHS IN PORTUGAL: AN OBSERVATIONAL STUDYVALUE IN HEALTHIF62016-11-010OAAI
A SYSTEMATIC REVIEW ON THE EPIDEMIOLOGY OF NRAS-MUTANT MELANOMA IN EUROPE AND AUSTRALIAVALUE IN HEALTHIF62016-11-010OAAI
USE OF A CLAIMS DATABASE TO DOCUMENT THE USE AND EFFECTIVENESS OF ORAL VINORELBINE (NVBO) IN A REAL WORLD SETTING FRANCEVALUE IN HEALTHIF62016-11-010OAAI
DEVELOPMENT OF A VALIDATED QUESTIONNAIRE EVALUATING THE BURDEN OF THE HAEMORRHOIDAL DISEASE AND ANAL FISSURE (HEMO-FISS)VALUE IN HEALTHIF62015-11-013OAAI
COST COMPARISON OF ORAL VERSUS IV VINORLBINE IN FRANCE IN ADVANCED BREAST CANCERVALUE IN HEALTHIF62015-11-010OAAI
HEALTH RELATED QUALITY OF LIFE OF CAREGIVERS AND PATIENTS TREATED FOR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH ORAL VINORELBINEVALUE IN HEALTHIF62015-11-013OAAI
BURDEN OF ADVANCED BREAST CANCER FOR PATIENTS AND CAREGIVER IN EUROPE: COMPARISONS OF TWO TREATMENT FORMS OF VINORELBINE, ORAL AND INTRAVENOUSVALUE IN HEALTHIF62015-11-011OAAI
INFLUENCE OF THE METHOD OF ANALYSIS ON ESTIMATES OF QALY TREATMENT DIFFERENCE: PHASE III TRIAL OF VINFLUNINE VERSUS BEST SUPPORTIVE CARE IN PATIENTS WITH TCCUVALUE IN HEALTHIF62015-11-010OAAI
COST-UTILITY ANALYSIS OF LINACLOTIDE IN THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN BELGIUMVALUE IN HEALTHIF62013-11-010OAAI
BUDGET IMPACTS OF PROBIOTICS IN CONTROLLING UPPER RESPIRATORY TRACT INFECTIONS IN FRANCEVALUE IN HEALTHIF62013-11-010OAAI
THE CURRENT MANAGEMENT AND COSTS OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN BELGIUM: A 2-ROUND EXPERT SURVEYVALUE IN HEALTHIF62013-11-010OAAI
PUBLIC HEALTH IMPACTS OF PROBIOTICS IN CONTROLLING UPPER RESPIRATORY TRACT INFECTIONS IN FRANCEVALUE IN HEALTHIF62013-11-010OAAI
LONG TERM EFFECTIVENESS OF LIMBAL RELAXING INCISION (LRI) DURING CATARACT SURGERY TO CORRECT ASTIGMATISMVALUE IN HEALTHIF62011-11-010OAAI
ECONOMIC OUTCOMES OF GLAUCOMA TREATMENT WITH PROSTAGLANDIN EYE DROPS PRESERVED WITH POLYQUAD® INSTEAD OF BENZALKONIUM CHLORIDE IN GERMANYVALUE IN HEALTHIF62011-11-010OAAI
ND-YAG LASER INCIDENCE RATE COMPARISON OF THREE MONOFOCAL INTRAOCULAR LENSES (IOL) 36 MONTHS AFTER CATARACT SURGERY IN FRANCEVALUE IN HEALTHIF62011-11-010OAAI
OCULAR DISCOMFORT, COMPLIANCE AND INTRA-OCULAR PRESSURE (IOP) CONTROL IN PATIENTS TREATED FOR GLAUCOMAVALUE IN HEALTHIF62011-11-012OAAI